Emerging Biotech MAIA Strengthens Research Leadership to Accelerate Drug Development

Rhea-AI Filing Summary

MAIA Biotechnology (NYSE: MAIA) announced the appointment of new members to its Scientific Advisory Board on June 24, 2025. The company, an emerging growth company listed on NYSE American, filed this 8-K to disclose the board expansion.

Key aspects of the filing include:

• The announcement was made through a press release (Exhibit 99.1)
• The company maintains its headquarters at 444 West Lake Street, Chicago
• The filing includes standard forward-looking statements highlighting potential risks in areas such as:
  • Clinical study initiation, timing, and results
  • Regulatory approval processes
  • Product development and manufacturing capabilities
  • Market acceptance and commercialization potential
  • Intellectual property protection

The document was signed by Vlad Vitoc, Chief Executive Officer of MAIA Biotechnology.

Positive

• Addition of new members to scientific advisory board strengthens company's scientific expertise and research capabilities

Negative

• None.

false 0001878313 0001878313 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2025

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 24, 2025, the Company issued a press release announcing the appointment of additional members to its scientific advisory board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated June 24, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 24, 2025

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3

FAQ

Why did MAIA Biotechnology (MAIA) file an 8-K on June 24, 2025?

MAIA Biotechnology filed an 8-K to announce the appointment of additional members to its scientific advisory board. The company issued a press release regarding these appointments, which was included as Exhibit 99.1 in the filing.

Who signed MAIA Biotechnology's June 24, 2025 8-K filing?

The 8-K filing was signed by Vlad Vitoc, who serves as the Chief Executive Officer of MAIA Biotechnology, Inc.

Is MAIA Biotechnology (MAIA) considered an emerging growth company?

Yes, MAIA Biotechnology is classified as an emerging growth company as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, as indicated by the checked box in the filing.

What risks did MAIA Biotechnology disclose in their June 2025 8-K?

MAIA disclosed several key risks in their forward-looking statements, including: (i) risks related to preclinical and clinical studies timing and results, (ii) ability to advance product candidates through clinical studies, (iii) timing of regulatory approvals, (iv) manufacturing and commercialization capabilities, (v) market acceptance of products, (vi) market size and growth potential, and (vii) ability to maintain intellectual property protection.

Where is MAIA Biotechnology's headquarters located?

MAIA Biotechnology's principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.